This page is updated frequently with new Cytokine-related patent applications.
| Systems and methods for detecting infectious diseases|
Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (pos) location and may be tested at the pos location for multiple markers for multiple diseases, including upper and lower respiratory diseases.
| Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities|
Disclosed herein are il-4 cytokine compositions with enhanced biological activity having increased selectivity for il-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (il-4) muteins.
| Tissue protective peptides and uses thereof|
The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex.
Araim Pharmaceuticals, Inc.
| Combination therapy with anti-cd74 and anti-cd20 antibodies provides enhanced toxicity to b-cell diseases|
Disclosed are compositions and methods comprising combinations of anti-cd74 and anti-cd20 antibodies or antigen-binding fragments thereof. The antibody combination may also be used with a therapeutic agent that is attached to antibody or fragment thereof or separately administered.
Ibc Pharmaceuticals, Inc.
| Compositions including il-18 and il-22 and their use in anti-viral therapies|
The present invention is directed to compositions including the cytokines il-18 and il-22 or biologically active fragments or variants thereof. In some embodiments, the compositions further include a pharmaceutically acceptable carrier.
Georgia State University Research Foundation, Inc.
|Adipose derived adult stem cells in hepatic regeneration|
The present invention provides a method to derive hepatic stem cells from stem cells derived from non-liver tissue. In one embodiment of the invention, hepatic stem cells are derived from adipose stem cells.
|Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines|
This invention provides a method to prevent, control, and/or treat an inflammatory disease or disorder by administering at least one agonist of guanalyte cyclase receptor, or pharmaceutical compositions thereof, either alone or either concurrently or sequentially with another compound or an active agent used to treat the disease or disorder, and/or with an inhibitor of cgmp-dependent phosphodieasterases.. .
Synergy Pharmaceuticals, Inc.
|Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal|
Adult autologous stem cells cultured on a porous, three-dimensional tissue scaffold-implant for bone regeneration by the use of a hyaluronan and/or dexamethasone to accelerate bone healing alone or in combination with recombinant growth factors or transfected osteogenic genes. The scaffold-implant may be machined into a custom-shaped three-dimensional cell culture system for support of cell growth, reservoir for peptides, recombinant growth factors, cytokines and antineoplastic drugs in the presence of a hyaluronan and/or dexamethasone alone or in combination with growth factors or transfected osteogenic genes, to be assembled ex vivo in a tissue incubator for implantation into bone tissue..
|Transdiscal administration of specific inhibitors of pro-inflammatory cytokines|
The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.. .
Depuy Synthes Products, Inc.
|Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor|
An hdac6 inhibitor (a compound of formula i) is shown to reduce the pathogenesis associated with the b cell mediated autoimmune disease, systemic lupus erythematosus (sle) administration of a compound of formula i attenuated many of the symptoms characteristic of sle including splenomegaly, abnormal b cell differentiation, an increase in the number double-negative thymic t cells, an increase in the level of auto-antibodies such as anti-dsdna, immune complex-mediated glomerulonephritis and an increase in inflammatory cytokine production. Treatment with a compound of formula i also increased the number of the subject's splenic treg cells while removing circulating auto-antibodies inhibition of hdac6 altered bone marrow b cell differentiation by increasing the percentage of cells in the early-stage developmental fractions of both pro- and pre-b cells.
Virginia Tech Intellectual Properties, Inc.
Medical devices containing rapamycin analogs
A medical device comprises a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature.
Methods for treating ophthalmic disorders, diseases and injuries
The invention is directed to methods for treating ophthalmic disorders, diseases and injuries. In particular, the invention is directed to treating disorders, diseases and injuries of the cornea and ocular surface.
Noveome Biotherapeutics, Inc.
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
Treatment of autoimmune and/or inflammatory diseases associated with overexpression of toll-like receptor 3 (tlr3) as well as toll-like receptor 4 (tlr4) and/or tlr3/tlr4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with tlr3 as well as tlr4 and/or tlr3/tlr4 cellular signaling in association with related pathologies is disclosed.
Plasmonic beads for multiplexed analysis by flow detection systems
Disclosed are methods and assays for detection of low concentration analytes such as proteins in a sample, using beads. Specially coated beads allow for femtomolar sensitivity through strong near-infrared fluorescence enhancement on plasmonic beads having gold nanostructures in a coating.
The Board Of Trustees Of The Leland Stanford Junior University
Icos binding proteins
The present invention relates to an icos binding protein, or antigen binding portion thereof that is an agonist human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.
Glaxosmithkline Intellectual Property Development Limited
Human immune therapies using a cd27 agonist alone or in combination with other immune modulators
Methods of inducing t cell proliferation and expansion in vivo for treating conditions wherein antigen-specific t cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one cd27 agonist, preferably an agonistic cd27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-cd40, ox-40, 4-1bb, or ctla-4 antibody or an agent that depletes regulatory cells, or a cytokine.
University Of Southampton
The present invention relates to methods of and compositions comprising cytokines for, improving the success rate of embryo implantation and the success rate of pregnancy rates in females, by providing an immunopermissive uterine environment prior to insemination or implantation of embryos. The methods of the present invention are used to make the uterus more receptive or less hostile to, for example, transferred embryos, sperm or other allografted tissue..
Ostara Biomedical Ltd
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
Methods of assessing or monitoring the effect, efficacy, responsiveness to treatment, and/or determining a dose or dosing regimen of therapeutic agents, such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of using integrin beta7 subunit-containing receptor occupancy by the integrin beta7 antagonist on colonic lymphocytes as an indicator (“biomarker”) of the effect, efficacy, or responsiveness to treatment, and/or as a means to determine dosing or dosing regimens of therapeutic agents such as beta7 integrin antagonists for the treatment of gastrointestinal inflammatory disorders are provided.
Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hghrelin.. .
Ipsen Pharma S.a.s.
Method for treating cognitive dysfunction
The present invention provides compositions and methods for treating cognitive impairment or dysfunction in a subject. In particular, the present invention provides a method for using a composition comprising an angiotensin-(1-7) receptor agonist to treat cognitive dysfunction or impairment that is due to a various clinical conditions including, but not limited to, those associated with increase in inflammation, cytokine production, increases in reactive oxygen species, changes in expression of brain inflammatory related genes and/or in the expression of genes involved in learning and memory within the central nervous system of a subject..
Arizona Board Of Regents For The University Of Arizona
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
Provided herein are embodiments relating to therapeutic applications of antibodies that modulate; e.g., inhibit the interaction of tim-3 and lilrb2 antibodies. In some embodiments, the antibodies bind tim-3.
Jounce Therapeutics, Inc.
Scaffolds containing cytokines for tissue engineering
The present disclosure provides biocompatible scaffold that promotes m1 or m2 macrophage phenotypes so as to increase vascularization or healing. Also provided are methods of treating a subject in need with the scaffolds described here..
The Trustees Of Columbia University In The City Of New York
Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of il-4 in el-4 cells, which are mouse t cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube.
Korea Research Institute Of Bio Science And Biotechnology
Substituted imidazo ring systems and methods
Imidazo ring systems substituted at the 1-position, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.. .
3m Innovative Properties Company
Partial peptide of survivin presented on mhc class ii molecule and use thereof
The object aims to provide: a novel tumor antigen; a novel therapeutic agent useful in a method for treating a malignant neoplasm by utilizing the tumor antigen; and a tumor antigen which can be used as the therapeutic agent. Thus, disclosed are: a novel tumor antigen which has an epitope capable of inducing a th1 cell which is a cd4-positive t cell specific to survivin; and use of the tumor antigen.
Immunogenic compositions and methods for treating neoplasia
The invention provides immunogenic compositions comprising neoplastic cells expressing a cytokine (gm-csf) formulated with at least one tlr agonist and methods of using the composition to induce or enhance an immune response.. .
The Johns Hopkins University
Cell permeable inhibitors of the scaffold protein plenty of sh3 domains (posh) or sh3rfl
Plenty of sii3 (posh) and ink-interacting protein 1 (jip-1) function as a multi-protein scaffold network for tcr-mediated jnk1 activation in cd8+ t-cells. Disruption of the posh/jip-1 complex led to profound defects in the activation of jnk1, as well as deficient activation or induction of the transcription factors c-jun, t-bet and eomesodermin furthermore, disruption of the posh/jip complex in cd8+t-cells resulted in impaired proliferation, decreased cytokine expression and the inability to control tumors.
The Curators Of The University Of Missouri
Treatment of inflammatory diseases by carbon materials
In some embodiments, the present disclosure pertains to methods of treating an inflammatory disease in a subject by administering a carbon material to the subject. In some embodiments, the carbon material selectively targets t cells in the subject.
Baylor College Of Medicine
Composition for preventing and treating immune diseases containing daurinol compound as active ingredient
The daurinol compound according to the present invention exhibits excellent therapeutic effects on arthritis and inflammatory bowel diseases by having an excellent activity in inhibiting the generation of il-17 and tnf-α, which are inflammatory cytokines causing inflammation, and can alleviate transplant rejection by inhibiting the proliferation of alloreactive t cells and increasing regulatory t cells; therefore, the daurinol compound according to the present invention can be used as a pharmaceutical composition capable of treating and preventing immune diseases. In addition, being a natural substance derived from the mongolian medicinal plant haplophyllum dauricum or haplophyllum cappadocicum, the daurinol compound according to the present invention does not cause cytotoxicity and thus may be used as a composition for a functional health food capable of preventing and remedying immune diseases..
The Catholic University Of Korea Industry-academic Cooperation Foundation
Methods for therapeutic renal neuromodulation
Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
Methods for bilateral renal neuromodulation
Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
Humanized mice expressing the pyrin domain only protein 2
A transgenic mouse expressing the human gene for pyrin domain-only protein 2 (pop2). Pop2, when expressed in the transgenic mouse model, broadly dampens inflammatory cytokine production, in part through restricting the activation of both nlrp3 and aim2 inflammasomes.
Albany Medical College
Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
A composition includes monoclonal antibodies directed against a circulating proinflammatory cytokine, the antibodies having a high affinity for the fcγriiia receptor (cd16), in particular the fucose level of all of the antibodies of the composition being less than 60%, and preferably less than 50%, and in particular, the galactosylation level of all of the antibodies of the composition being at least 60%, for the use thereof in the context of the prevention or treatment of the early phases of inflammation. A composition including monoclonal antibodies directed against a circulating bacterial toxin, having an improved affinity for the fcγriiia receptor (cd16) with respect to antibodies directed against the bacterial toxin, produced in the cho cell line, for the use thereof in the context of the prevention or treatment of the early phases of a bacterial infection linked to the release of the toxin is also described..
Suppression of cytokine release and cytokine storm
The present invention includes methods and compositions for ameliorating symptoms or treating one or more adverse reactions triggered by infectious diseases or disease conditions that trigger a widespread release of cytokines in a subject comprising the steps of: identifying the subject in need of amelioration of symptoms or treatment of the infectious diseases or disease conditions that trigger a widespread release of cytokines; and administering one or more pharmaceutical compositions comprising a therapeutically effective amount of a curcumin extract, curcuminoids or synthetic curcumin (s-curcumin) and derivatives thereof, or empty liposomes, dissolved or dispersed in a suitable aqueous or non-aqueous medium sufficient to reduce the level of cytokines in the host.. .
Methods for monopolar renal neuromodulation
Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Cd40l collectin fusion proteins
The present invention refers to a fusion protein comprising a tnf-superfamily (tnfsf) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof.
Peptide for suppressing osteoclast differentiation and use thereof
The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (il)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of nf-κb and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-b ligand (rankl)-rank signaling pathway, and suppresses the expression of a rankl or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (trap), cathepsin k, or tnf receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration.
Il-15 and il-15raplha sushi domain based modulokines
The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an immunomodulatory antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide comprising the amino acid sequence of the sushi domain of the il-15rα or derivatives thereof; and uses thereof.. .
Chimeric immunoreceptor useful in treating human cancers
The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of t lymphocytes, direct t cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific.
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
The present invention relates to the combination therapy of specific tumor-targeted il-2 variant immunocytokines with specific antibodies which bind human pd-l1.. .
Methods for identifying autoimmune arthritis and for screening for inhibitor of activation of autoimmune arthritogenic t cells
Provided are a method for identifying the presence or likelihood of autoimmune arthritis, the method comprising detecting (1) an anti-ribosomal protein l23a antibody or (2) ribosomal protein l23a-reactive cd4+ t cells in a sample derived from a subject; and a method for screening for a substance that inhibits the activation of autoimmune arthritogenic t cells, the method comprising the steps of bringing a test substance into contact with ribosomal protein l23a-reactive t cells, bringing the t cells into contact with ribosomal protein l23a or a fragment thereof, measuring the level of a proinflammatory cytokine secreted from the t cells, and analyzing the test substance-dependent change in the secretion level of the proinflammatory cytokine.. .
Targeting of cytokine antagonists
The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling.
Centre Hospitalier Regional Universitaire De Montpellier
Targeted modified tnf family members
The present invention relates to a modified cytokine of the tnf superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the tnf superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells.
Centre Hospitalier Regional Universitaire De Montpellier
Targeted modified il-1 family members
The present disclosure relates to a modified interleukin-1 (il-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the il-1 family member cytokine is a mutant, more preferably it is a mutant il-1 with low affinity to the il-1 receptor, wherein said mutant il-1 is specifically delivered to target cells.
Centre Hospitalier Regional Universitaire De Montpellier
Use of a cd6 binding partner and method based thereon
The present disclosure relates to methods for treatment and prevention of disease conditions mediated by t-helper 17 (th17) and/or t-helper 1 (th1) t lymphocytes (t cells). In particular, the present disclosure relates to use of anti-cd6 antibody for treatment of disease conditions mediated by auto-reactive th17 and th1 t lymphocytes.
Center Of Molecular Immunology
Vaccines using high-dose cytokines
The present invention relates to the field of cancer immunotherapy. In particular, vaccines are administered in conjunction with high doses of cytokines to enhance an anti-tumor immune response..
Sunnybrook And Women's College Health Sciences Center
Antibody and cytokine biomarker profiling for determination of patient responsiveness
Compositions and methods are provided for prognostic classification of autoimmune disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of circulating blood levels of serum autoantibodies and/or cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness.
The Board Of Trustees Of The Leland Stanford Junior University
Receptors for b7-h4
Isolated cell surface receptors for b7-h4 have been identified based on function. B7-h4 receptor activation by b7-h4 on the dendritic cell, t follicular helper cell and germinal center b cell membrane stimulates inhibitory signaling in those leukocytes.
Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
Psa is delivered to the host by outer membrane vesicles (omvs), secretion structures that target bacterial molecules to host cells. Purified omvs direct the in vitro differentiation of functional tregs with potent suppressive activity in a psa dependent manner.
California Institute Of Technology
Targeting type i nkt cells to control inflammation
Embodiments are directed to methods and compositions for modulating cytokine responses in subject infected by a pathogen.. .
The Board Of Regents Of The University Of Texas System
Production and therapeutic uses of th1-like regulatory t cells
A unique cd4+cd25+ regulatory t cell population develops from naive cd4+cd25− t cells during a th1 polarized immune response (called th1-tr cells). These th1-tr cells can be generated by contacting naïve t cells with mature cd8α+ dendritic cells (dcs) that have been exposed to a th1 polarizing adjuvant and, in some cases, an antigen of interest.
The Board Of Trustees Of The Leland Stanford Junior University
Biomarker for psychiatric and neurological disorders
The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free κ immunoglobulin chains and free λ immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders.
Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same
Provided are isolated nucleic acid molecules encoding chimeric antigen receptors (cars) that bind to tumor antigens. Also provided are isolated polypeptides and cars encoded by the isolated nucleic acid molecules, vectors that include the isolated nucleic acid molecules, cells that include the isolated nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered t cells in a subject, expanding a population of genetically engineered t cells in a subject, modulating the amount of cytokine secreted by a t cell, reducing the amount of activation-induced calcium influx into a t cell, providing an anti-tumor immunity to a subject, treating a mammal having a muc1-associated disease or disorder, stimulating a t cell-mediated immune response to a target cell population or tissue in a subject, and imaging a muc1-associated tumor..
The University Of North Carolina At Charlotte
Immunoprotective primary mesenchymal stem cells and methods
Immunoprotective primary mesenchymal stems cells (ip-msc) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The ip-msc express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (scfv), fab or f(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., il-2, il-4, il-6, il-7, il-9, and il-12), an interferon (e.g., ifnα, ifnβ, or ifnω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides..
The Administrators Of The Tulane Educational Fund
Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (at-car) system which provides t cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αfitc-car-expressing t cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive fitc-labeled antibodies.
University Of Maryland, Baltimore
Compounds and methods for affecting cytokines
The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of tnf-a, lactoferrin, ifn-γ, il-i β, serum amyloid-a (saa), il-6 and/or β-defensin associated with infection or an immune response generally..
Zivo Biosciences, Inc.
Systems and methods for characterizing kidney diseases
The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine.
Immunologically active polypeptide
Disclosed are immunomodulatory polypeptides that behave as weak tlr2 and tlr4 agonists and as potent competitive antagonists of natural pathogenic ligands for human and murine tlr2 and tlr4, that identify a subset of neutrophils in human peripheral blood leukocytes, and that elicit an unusual induced cytokine profile. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry.
Institute Of Arthritis Research, Llc
Administration of an anti-interleukin 12/23 antibody for treatment of autoimmune disease
The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of ustekinumab is administered to the subject.
Treatment of skeletal voids with implantable substrate hydrated with bone marrow concentrate
The invention is directed to a bone void filler comprising a scaffold or matrix. The scaffold or matrix may include a porous inorganic matrix component.
Spinesmith Partners, L.p.
Methods for accelerating the healing of connective tissue injuries and disorders
The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments.
Inflammatory disease diagnosis and methods of treatment using lipopolysaccharides-responsive beige-like anchor
Anti-cytokine therapy has revolutionized immunological disease treatment, but is not always effective and subject to treatment resistance as the cytokine cascade is highly redundant and multiple cytokines are involved in inflammation. Targeting a critical common regulator of inflammatory effectors is desirable.
Recombinant cancer therapeutic cytokine
Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of mda-7/tl-24 (“m4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to mda-7/il-24 receptors on adjacent, neighboring and distant cancer cells.